» Authors » James E Kendrick

James E Kendrick

Explore the profile of James E Kendrick including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 32
Citations 311
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Holloway R, Ahmad S, Kendrick J, Bigsby G, Brudie L, Ghurani G, et al.
Ann Surg Oncol . 2017 Mar; 24(7):1972-1979. PMID: 28265777
Background: This prospective cohort study aimed to assess sentinel lymph node (SLN) mapping using isosulfan blue (ISB) compared with ISB plus indocyanine green (ICG) and near-infrared imaging (NIR) for patients...
12.
Gubbi A, Kacheria S, Ahmad S, Stavitzski N, Kendrick J
Int J Gynecol Cancer . 2017 Feb; 27(3):530-536. PMID: 28187100
Objectives: To determine the prognostic significance of the pretreatment and posttreatment maximum standardized uptake value (SUVmax) of F-labeled 2-fluoro-2-deoxyglucose positron emission tomography (PET)/computed tomography imaging in patients with stage IB2-IVA...
13.
McCourt C, Deng W, Dizon D, Lankes H, Birrer M, Lomme M, et al.
Gynecol Oncol . 2016 Dec; 144(1):101-106. PMID: 28029447
Background: The primary objectives were to determine the objective response rate (ORR) and safety profile of ixabepilone in women with recurrent or persistent uterine carcinosarcoma (UCS). Secondary objectives included progression-free...
14.
Holloway R, Gupta S, Stavitzski N, Zhu X, Takimoto E, Gubbi A, et al.
Gynecol Oncol . 2016 Feb; 141(2):206-210. PMID: 26905211
Objectives: To compare the performance of sentinel lymph node (SLN) mapping with staging lymphadenectomy versus staging lymphadenectomy alone for the detection of metastasis and the use of adjuvant therapies in...
15.
Makker V, Filiaci V, Chen L, Darus C, Kendrick J, Sutton G, et al.
Gynecol Oncol . 2015 Apr; 138(1):24-9. PMID: 25888978
Objective: This two-stage phase II study assessed activity of single agent dalantercept in patients with recurrent/persistent endometrial carcinoma (EMC). Methods: Eligible patients had persistent/recurrent EMC after 1-2 prior cytotoxic regimens,...
16.
Gubbi A, Kendrick J, Finkler N
Expert Rev Anticancer Ther . 2014 Sep; 14(10):1105-13. PMID: 25189201
The majority of women with ovarian cancer will experience a recurrence of their disease despite aggressive primary cytoreduction and adjuvant cytotoxic chemotherapy. Notwithstanding the high rate of recurrence, targeted and...
17.
Alvarez E, Brady W, Walker J, Rotmensch J, Zhou X, Kendrick J, et al.
Gynecol Oncol . 2012 Dec; 129(1):22-7. PMID: 23262204
Objective: This two-stage phase II study was designed to assess the activity of the combination of temsirolimus and bevacizumab in patients with recurrent or persistent endometrial carcinoma (EMC). Methods: Eligible...
18.
Bevis K, Straughn Jr J, Kendrick J, Walsh-Covarrubias J, Kilgore L
J Grad Med Educ . 2012 Mar; 3(1):100-3. PMID: 22379530
Background: Residency program directors are challenged to effectively teach and assess the Accreditation Council for Graduate Medical Education's (ACGME) 6 competencies. The purpose of this study was to characterize the...
19.
Greer H, Frederick P, Falls N, Tapley E, Samples K, Kimball K, et al.
Int J Gynecol Cancer . 2010 Nov; 20(8):1321-5. PMID: 21051971
Background: The objective of this study was to evaluate the impact of a weekly tumor board conference on the management of patients with gynecologic malignancies. Methods: The medical records of...
20.
Sfakianos G, Frederick P, Kendrick J, Straughn J, Kilgore L, Huh W
Int J Med Robot . 2010 Sep; 6(4):405-12. PMID: 20848676
Background: In order to understand how robotic surgery impacts gynecologic oncology fellowship training and surgical practices, a survey of fellows and fellowship directors was conducted. Methods: Questionnaires designed to determine...